Alison Moore - Codexis Chief Officer
| CDXS Stock | USD 4.33 0.08 1.88% |
Executive
Alison Moore is Chief Officer of Codexis
| Age | 57 |
| Address | 200 Penobscot Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 421 8100 |
| Web | https://www.codexis.com |
Alison Moore Latest Insider Activity
Tracking and analyzing the buying and selling activities of Alison Moore against Codexis stock is an integral part of due diligence when investing in Codexis. Alison Moore insider activity provides valuable insight into whether Codexis is net buyers or sellers over its current business cycle. Note, Codexis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Codexis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Alison Moore over three months ago Acquisition by Alison Moore of 432738 shares of Allogene Therapeutics at 5.04 subject to Rule 16b-3 |
Codexis Management Efficiency
The company has return on total asset (ROA) of (0.2095) % which means that it has lost $0.2095 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7531) %, meaning that it created substantial loss on money invested by shareholders. Codexis' management efficiency ratios could be used to measure how well Codexis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.54 in 2024. Return On Capital Employed is likely to drop to -0.71 in 2024. At this time, Codexis' Non Currrent Assets Other are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 170.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 36.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Suresh Silva | Shattuck Labs | N/A | |
| Kristian MBA | Foghorn Therapeutics | 48 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Jeremy Chadwick | Kymera Therapeutics | 61 | |
| Michael Naso | Century Therapeutics | N/A | |
| Alicia Hager | Nkarta Inc | 54 | |
| Jason Kantor | Nurix Therapeutics | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| Neel Anand | Kezar Life Sciences | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Conor CPA | Shattuck Labs | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| David MD | Nkarta Inc | 46 | |
| Alfonso MD | Foghorn Therapeutics | 53 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Cristiana Guiducci | Nurix Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.21 |
Codexis Leadership Team
Elected by the shareholders, the Codexis' board of directors comprises two types of representatives: Codexis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Codexis. The board's role is to monitor Codexis' management team and ensure that shareholders' interests are well served. Codexis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Codexis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sriram MBA, Chief Officer | ||
| Georgia Erbez, Chief Officer | ||
| MBA Taylor, VP CFO | ||
| Asli Aras, VP Devel | ||
| Margaret JD, General Officer | ||
| John Schiffhauer, Senior Property | ||
| Stephen MBBS, CEO President | ||
| Rob Wilson, VP Enzymes | ||
| MS MBA, Chief Officer | ||
| Carrie McKim, Director Relations | ||
| John Nicols, CEO and President and Director | ||
| Karen FrechouArmijo, Senior Resources | ||
| Karl Schoene, Sr Operations | ||
| Robert MBA, Quality Development | ||
| Alison Moore, Chief Officer | ||
| Stefan Lutz, Senior Research |
Codexis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Codexis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (1.29) % | ||||
| Current Valuation | 303.96 M | ||||
| Shares Outstanding | 81.38 M | ||||
| Shares Owned By Insiders | 2.22 % | ||||
| Shares Owned By Institutions | 79.80 % | ||||
| Number Of Shares Shorted | 1.95 M | ||||
| Price To Earning | (16.02) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Codexis Stock Analysis
When running Codexis' price analysis, check to measure Codexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codexis is operating at the current time. Most of Codexis' value examination focuses on studying past and present price action to predict the probability of Codexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Codexis' price. Additionally, you may evaluate how the addition of Codexis to your portfolios can decrease your overall portfolio volatility.